Schonfeld Strategic Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,068	Closed	-$2.37M	–	2670
2023 Q1	$2.37M	Buy	22,068 +2,094	+10%	+$241K	0.02%	648
2022 Q4	$2.2M	Sell	19,974 -46,676	-70%	-$3.03M	0.02%	786
2022 Q3	$3.93M	Buy	+66,650	New	+$3.05M	0.03%	608

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Schonfeld Strategic Advisors's RXDX Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 22,068 shares — an estimated $2.37M sold.

Schonfeld Strategic Advisors first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $3.93M in Q3 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Schonfeld Strategic Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 22,068 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.37M.
Schonfeld Strategic Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Schonfeld Strategic Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $3.93M in Q3 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.